DRMA: Dermata Therapeutics, Inc.
Dilution Risk Score 90/100

Dermata Therapeutics, Inc. (DRMA) carries a Critical dilution risk score of 90 out of 100 based on DilutionWatch's real-time analysis of SEC EDGAR filings. Contributing factors include 7 dilutive SEC filings in the past 12 months.

Why DRMA Has a Critical Dilution Risk Score

DilutionWatch scores every ticker on a 0–100 scale by analyzing five components: cash runway, warrant overhang, convertible securities, active shelf/ATM capacity, and historical filing patterns. A score of 90 means DRMA is in the highest-risk category across multiple dimensions simultaneously.

• Cash runway: Estimated at 9.0 months — moderate, but ongoing losses will require additional capital
• Warrant overhang: Outstanding warrants represent 39% of current shares outstanding — significant potential dilution if exercised at or near current prices
• Convertible securities: Convertible notes/instruments represent 61% of current shares — material dilution risk if converted
• Filing pattern: 7 dilutive filings in the past 12 months (last: 2026-01-29), indicating a pattern of repeat capital raises

Recent SEC Filing History for DRMA

The following dilutive filings have been detected for DRMA in the past 12 months via DilutionWatch's real-time EDGAR monitoring:

How to Monitor DRMA for Dilution Alerts

DilutionWatch polls SEC EDGAR every 60 seconds. When Dermata Therapeutics, Inc. files an S-3, 424B, 8-K financing disclosure, or any of 25 tracked filing types, you receive an alert before the stock reprices. This is the same monitoring capability that institutional traders use — available to retail investors through DilutionWatch's free tier.

Additional Investor Analysis: DRMA Dilution Risk Insights

Historical Patterns of Critical Risk Levels for Retail Investors

A dilution risk score of 90/100 is historically a red flag for retail investors, often signaling a high probability of significant dilution events in the near term. When companies reach this level, they typically have substantial warrant or equity issuance plans in motion, often accompanied by weak cash positions and aggressive capital-raising strategies. Retail shareholders who have held stocks at this risk level have frequently seen their ownership percentages erode rapidly through new share issuances, particularly in cases involving PIPE deals or shelf offerings. Historically, stocks with such scores have underperformed compared to sector peers, and many have seen sharp declines post-dilution events.

SEC Filings to Monitor

Investors tracking DRMA should closely monitor several key SEC filings:

• S-3 Registration Statements – These indicate potential large-scale equity offerings, often used for shelf registrations that can be quickly activated.
• 8-K Reports – These are critical for tracking material events such as new financing rounds, warrant exercises, or changes in capital structure.
• 424B5 Forms – Used to file prospectuses for shelf offerings and other equity transactions; often appear before large issuances.

These filings are available through the EDGAR database, and monitoring them in real time can help investors identify upcoming dilution events.

DilutionScore vs. Sector Averages

DRMA’s score of 90/100 places it well above the average dilution risk score for its sector, which typically hovers around 40–50 for biotech and specialty pharmaceutical companies. This elevated risk level suggests that DRMA is likely experiencing more aggressive fundraising strategies than peers, possibly due to financial strain or rapid growth plans that require substantial capital. Investors can compare this risk level using the DilutionWatch or view broader sector trends in the .

Next Steps for Investors

For investors monitoring DRMA, the key is proactive surveillance. Set up alerts on EDGAR filings and watch for changes in cash runway and warrant overhang using tools like the Warrant Tracker. Additionally, keep an eye on any upcoming shelf or ATM offerings via the Shelf & ATM Monitor, as these often precede large dilution events. Consider reviewing recent performance and cash burn metrics to assess whether the company is effectively utilizing capital.